These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24648755)

  • 1. Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer.
    Saksena R; Wong ST
    Breast Cancer (Dove Med Press); 2013; 5():27-35. PubMed ID: 24648755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes.
    Jerusalem G; Rorive A; Collignon J
    Breast Cancer (Dove Med Press); 2014; 6():43-57. PubMed ID: 24833916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K/AKT/mTOR.
    Wang R; Zhu QY; Ye WW; Huang Y; Chen ZH; Zheng YB; Zou X; Wang J; Jiang DL; Wang XJ; Xu ZY; Cao WM
    Discov Med; 2024 Mar; 36(182):527-537. PubMed ID: 38531793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
    ; ; ;
    Zhonghua Zhong Liu Za Zhi; 2022 Jul; 44(7):673-692. PubMed ID: 35880333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.
    Dhillon S
    Drugs; 2013 Apr; 73(5):475-85. PubMed ID: 23529824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
    Barnett CM
    Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
    Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
    Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2.
    Hortobagyi GN
    Neoplasia; 2015 Mar; 17(3):279-88. PubMed ID: 25810012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer.
    Beck JT
    Onco Targets Ther; 2015; 8():3629-38. PubMed ID: 26675495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR inhibitors in advanced breast cancer: ready for prime time?
    Martin LA; André F; Campone M; Bachelot T; Jerusalem G
    Cancer Treat Rev; 2013 Nov; 39(7):742-52. PubMed ID: 23557794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer.
    Arena F
    Cancer Manag Res; 2014; 6():389-95. PubMed ID: 25336989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
    Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.
    Rugo HS
    Clin Breast Cancer; 2016 Feb; 16(1):18-22. PubMed ID: 26507507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus: a new hope for patients with breast cancer.
    Sendur MA; Zengin N; Aksoy S; Altundag K
    Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer.
    Sobhani N; Generali D; Zanconati F; Bortul M; Scaggiante B
    World J Clin Oncol; 2018 Dec; 9(8):172-179. PubMed ID: 30622925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases.
    Beck JT; Mantooth R
    Case Rep Oncol; 2015; 8(1):101-5. PubMed ID: 25848360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
    Baselga J; Campone M; Piccart M; Burris HA; Rugo HS; Sahmoud T; Noguchi S; Gnant M; Pritchard KI; Lebrun F; Beck JT; Ito Y; Yardley D; Deleu I; Perez A; Bachelot T; Vittori L; Xu Z; Mukhopadhyay P; Lebwohl D; Hortobagyi GN
    N Engl J Med; 2012 Feb; 366(6):520-9. PubMed ID: 22149876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
    Brufsky AM
    Breast J; 2014; 20(4):347-57. PubMed ID: 24861776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor: a new option].
    Gilabert M; Launay S; Gonçalves A
    Bull Cancer; 2014 Mar; 101(3):325-33. PubMed ID: 24691195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer.
    ; ;
    Cancer Innov; 2022 Jun; 1(1):25-54. PubMed ID: 38089455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.